Clinical Trial Update: Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2b safety and efficacy study of CGB-500 topical ointment containing 0.5% and 1% tofacitinib for atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CGB-500 topical ointment (tofacitinib)

Snippet

Sponsor: CAGE Bio Inc. | Conditions: Atopic Dermatitis (AD) | Phase 2 | Status: COMPLETED